flipper44,
Where do you get any of that out of what I posted? Linda is likely quietly building out capacity through Flaskworks microden production and will use that as leverage in any partnership deal. When she spends money to build she doesn’t let on easily any determination of her costs or plans. FDA wouldn’t want any leaks about preparedness either. They don’t want to catch any flak for holding things up at this point.
This is somewhat obviously a well coordinated effort to protect all the parties involved from feeling the repercussions of the extended process required for adequate preparation. Think back to when Les was trying to discuss the obvious 17 SOC/placebo patient under enrollment discrepancy in randomization, something the company had no clue about, by steering the conversation away from a deliberate mandate that no further SOC randomization would occur. Coordination. I believe you understand this but are frustrated by it all. I am too but as said my times here, we are along for the ride and that has been felt by NWBO insiders too who clearly have had a vision and a plan but less influence than hoped for in the way it all played out over time. That plea for help a while back sure seemed desperate to me but could also have been a ploy though I lean a little more towards desperate as perhaps a snafu in the development of Flaskworks, like you suggest, may have occurred. If nothing else, the product may have been ready too soon and Corning didn’t want to maintain dedicated space for it while waiting an unspecified time for orders. Best wishes.
Market Data 
Markets 
AI
